FindTrial
Sign In

Reassessing Statin Intolerance in China: Clinical Reality or Policy Artifact?

Reassessing Statin Intolerance in China: Clinical Reality or Policy Artifact?

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2600121713
Enrollment
Unknown
Registered
2026-04-01
Start date
2026-04-01
Completion date
Unknown
Last updated
2026-04-14

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Hyperlipidaemia, hypercholesterolaemia, hypertriglyceridaemia, statin intolerance

Interventions

The no adverse reaction group:None
The adverse reaction group:None

Sponsors

Beijing Friendship Hospital ,Capital Medical University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
No minimum to 100 Years

Inclusion criteria

Inclusion criteria: 1.History of statin use;

Exclusion criteria

Exclusion criteria: 1.Non-statin-induced myopathy, hepatopathy, renal disease;

Design outcomes

Primary

MeasureTime frame
statin intolerance;—

Secondary

MeasureTime frame
Age, Gender;—

Countries

China

Contacts

Public ContactRongchong Huang

Beijing Friendship Hospital ,Capital Medical University

rchuang@aliyun.com+86 10 6313 8217

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Apr 17, 2026